- Conditions
- Alzheimer Disease, Alzheimer Disease 1, Alzheimer Disease 10, Alzheimer Disease 11, Alzheimer Disease 12, Alzheimer Disease 13, Alzheimer Disease 14, Alzheimer Disease 15, Alzheimer Disease 16, Alzheimer Disease 17, Alzheimer Disease 18, Alzheimer Disease 19, Alzheimer Disease 2, Alzheimer Disease 3, Alzheimer Disease 4, Alzheimer Disease 5, Alzheimer Disease 6, Alzheimer Disease 7, Alzheimer Disease 8, Alzheimer Disease 9, Alzheimer Disease, Early Onset, Alzheimer Disease, Late Onset, Alzheimer's Dementia Late Onset, Cognitive Decline, Cognitive Impairment, Cognitive Impairment, Mild, Dementia, Dementia Alzheimers, Dementia Moderate, Dementia Senile, Dementia of Alzheimer Type, Dementia, Mild, MCI, Mild Cognitive Impairment, Mild Dementia
- Interventions
- Spectris™ AD - Active, Spectris™ AD - Sham
- Device
- Lead sponsor
- Cognito Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 670 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 68
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Sun City, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced May 21, 2026, 12:56 AM EDT